ATE286907T1 - Cytokinin-designiertes lerk-5 - Google Patents

Cytokinin-designiertes lerk-5

Info

Publication number
ATE286907T1
ATE286907T1 AT95926632T AT95926632T ATE286907T1 AT E286907 T1 ATE286907 T1 AT E286907T1 AT 95926632 T AT95926632 T AT 95926632T AT 95926632 T AT95926632 T AT 95926632T AT E286907 T1 ATE286907 T1 AT E286907T1
Authority
AT
Austria
Prior art keywords
lerk
cytokinin
designed
elk
polypeptides
Prior art date
Application number
AT95926632T
Other languages
English (en)
Inventor
Douglas P Cerretti
Pranhitha Reddy
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23037772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE286907(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE286907T1 publication Critical patent/ATE286907T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT95926632T 1994-07-08 1995-07-06 Cytokinin-designiertes lerk-5 ATE286907T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/271,948 US6303769B1 (en) 1994-07-08 1994-07-08 Lerk-5 dna
PCT/US1995/008534 WO1996001839A1 (en) 1994-07-08 1995-07-06 Novel cytokine designated lerk-5

Publications (1)

Publication Number Publication Date
ATE286907T1 true ATE286907T1 (de) 2005-01-15

Family

ID=23037772

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926632T ATE286907T1 (de) 1994-07-08 1995-07-06 Cytokinin-designiertes lerk-5

Country Status (14)

Country Link
US (4) US6303769B1 (de)
EP (1) EP0770088B1 (de)
JP (1) JPH10502810A (de)
AT (1) ATE286907T1 (de)
AU (1) AU684988B2 (de)
CA (1) CA2194299A1 (de)
DE (1) DE69533923T2 (de)
DK (1) DK0770088T3 (de)
ES (1) ES2236710T3 (de)
FI (1) FI965297A7 (de)
NO (1) NO965627L (de)
NZ (1) NZ290253A (de)
PT (1) PT770088E (de)
WO (1) WO1996001839A1 (de)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US6602683B1 (en) * 1995-10-25 2003-08-05 Regeneron Pharmaceuticals, Inc. Biologically active Eph family ligands
JP2001521368A (ja) * 1996-03-21 2001-11-06 イミュネックス・コーポレーション Ｌｅｒｋ―８と称すサイトカイン
US6413730B1 (en) 1996-07-05 2002-07-02 Mount Sinai Hospital Corporation Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
ATE318095T1 (de) 1999-12-13 2006-03-15 J R Crompton Ltd Aufgussbeutel und entsprechende herstellungsmaterialien
GB0002339D0 (en) 2000-02-02 2000-03-22 Crompton J R Plc Beverage infusion packages and materials therefor
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1606305A4 (de) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Nukleinsäureverbindungen für die inhibierung von angiogenese und tumorwachstum
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
EP2275445A3 (de) * 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
DE602005025459D1 (de) 2004-03-12 2011-02-03 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
EP1799867A2 (de) * 2004-09-23 2007-06-27 Vasgene Therapeutics, Inc. Zusammensetzungen und verfahren zur erkennung und behandlung von tumoren
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP1841790B1 (de) 2005-01-27 2010-11-03 The Burnham Institute Ephb-rezeptorbindende peptide
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
AU2006294873A1 (en) * 2005-09-23 2007-04-05 Vasgene Therapeutics, Inc. Use of EphrinB2 directed agents for the treatment or prevention of viral infections
KR20080066916A (ko) * 2005-10-05 2008-07-17 아쿠멘 바이오파마수티칼즈 케이.케이. 에프린 비2를 이용한 혈관신생 억제 방법
CN103193885B (zh) 2006-01-20 2015-05-13 健泰科生物技术公司 抗ephrinb2抗体及其使用方法
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
AU2008287427B2 (en) * 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4
RS56743B1 (sr) 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
EP3243527B1 (de) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunkonjugate mit einem intrazellulär spaltbaren linker
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2506881B1 (de) 2009-12-02 2024-03-06 Immunomedics, Inc. Kombination aus radioimmuntherapie und antikörper-arznei-konjugaten für verbesserte krebstherapie
DK2937349T3 (en) 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
EP2890696A1 (de) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinonverbindungen und derivate davon
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
CA2923145C (en) 2013-09-05 2025-09-16 Amgen Inc. MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
AU2017229575A1 (en) 2016-03-08 2018-09-27 Janssen Biotech, Inc. GITR antibodies, methods, and uses
MX419976B (es) 2016-07-14 2025-01-14 Scholar Rock Inc Anticuerpos de tgfb, métodos, y usos
CA3048217A1 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
ES2905676T3 (es) 2017-05-22 2022-04-11 Amgen Inc Inhibidores de KRAS G12C y métodos para su uso
CN111051306B (zh) 2017-09-08 2023-01-03 美国安进公司 Kras g12c的抑制剂及其使用方法
CN119639849A (zh) 2018-03-26 2025-03-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
EP3790886B1 (de) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c-inhibitoren zur behandlung von krebs
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
MX2021007157A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
EP3930845A1 (de) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclische heterocyclyl-verbindungen und ihre verwendung
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
CN114144414B (zh) 2019-05-21 2025-11-07 美国安进公司 固态形式
CN114302880B (zh) 2019-08-02 2025-07-15 美国安进公司 Kif18a抑制剂
US12540129B2 (en) 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
CA3147272A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
JP2023515235A (ja) 2019-10-31 2023-04-12 大鵬薬品工業株式会社 ４－アミノブタ－２－エンアミド誘導体及びその塩
PE20221277A1 (es) 2019-11-04 2022-09-05 Revolution Medicines Inc Inhibidores de ras
CN114786777A (zh) 2019-11-04 2022-07-22 锐新医药公司 Ras抑制剂
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
PE20230249A1 (es) 2019-11-08 2023-02-07 Revolution Medicines Inc Compuestos de heteroarilo biciclicos y usos de estos
TW202132271A (zh) 2019-11-14 2021-09-01 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
CA3158188A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
EP4065231A1 (de) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021126799A1 (en) 2019-12-18 2021-06-24 Merck Sharp & Dohme Corp. Macrocyclic peptides as potent inhibitors of k-ras g12d mutant
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
JP7373664B2 (ja) 2020-07-15 2023-11-02 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
AU2021345111B2 (en) 2020-09-15 2025-11-27 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
EP4267250A1 (de) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1-inhibitoren und verwendungen davon
CA3213636A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
EP4334324A1 (de) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
AR125782A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023064058A1 (en) 2021-10-12 2023-04-20 Peloton Therapeutics Inc. Tricyclic sultams and sulfamides as antitumor agents
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
IL314883A (en) 2022-03-07 2024-10-01 Amgen Inc Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4601644A1 (de) 2022-10-14 2025-08-20 Black Diamond Therapeutics, Inc. Verfahren zur behandlung von krebs mit isochinolin- oder 6-azachinolinderivaten
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4688790A1 (de) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Makrocyclische ras-inhibitoren
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025043187A1 (en) 2023-08-24 2025-02-27 Otsuka Pharmaceutical Co., Ltd. Fixed dose combinations of cedazuridine and azacitidine
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
TW202602929A (zh) 2024-03-21 2026-01-16 美商思進公司 Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134121A (en) 1988-03-28 1992-07-28 Regents Of The University Of California Nerve growth factor peptides
IL95511A (en) 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
IE911318A1 (en) 1990-04-23 1991-10-23 Yeda Res & Dev Use of a tumor necrosis factor for facilitating nerve¹regeneration
AU8931291A (en) 1990-10-16 1992-05-20 Regents Of The University Of Michigan, The Cytokine-induced marker for inflammatory response
WO1992018112A1 (en) 1991-04-19 1992-10-29 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
CA2111006C (en) 1991-06-21 2008-04-08 Andrew D. Boyd A novel receptor-type tyrosine kinase and use thereof
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
AU685765B2 (en) 1992-11-13 1998-01-29 Amgen, Inc. (Eck) receptor ligands
JPH06262882A (ja) 1993-03-12 1994-09-20 Dainippon Printing Co Ltd 香り入りカード付き帳票
DE9305552U1 (de) 1993-04-16 1993-06-03 MAN Roland Druckmaschinen AG, 6050 Offenbach Einrichtung zum Inline-Beschichten von Bedruckstoffen in Offsetdruckmaschinen
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5624899A (en) 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
WO1996011212A1 (en) * 1994-10-07 1996-04-18 Asahi Kasei Kogyo Kabushiki Kaisha Novel receptor-type tyrosine kinase ligand
JPH08188596A (ja) * 1994-10-19 1996-07-23 Asahi Chem Ind Co Ltd リセプター型チロシンキナーゼの新規なリガンド

Also Published As

Publication number Publication date
DE69533923D1 (de) 2005-02-17
US6492140B2 (en) 2002-12-10
US6479459B1 (en) 2002-11-12
US20020103358A1 (en) 2002-08-01
NO965627D0 (no) 1996-12-30
AU3094095A (en) 1996-02-09
FI965297L (fi) 1997-03-07
US20010009768A1 (en) 2001-07-26
NO965627L (no) 1997-03-07
JPH10502810A (ja) 1998-03-17
EP0770088A4 (de) 1999-10-13
CA2194299A1 (en) 1996-01-25
AU684988B2 (en) 1998-01-08
DE69533923T2 (de) 2006-01-12
FI965297A7 (fi) 1997-03-07
NZ290253A (en) 1998-02-26
ES2236710T3 (es) 2005-07-16
US6303769B1 (en) 2001-10-16
EP0770088A1 (de) 1997-05-02
WO1996001839A1 (en) 1996-01-25
PT770088E (pt) 2005-04-29
EP0770088B1 (de) 2005-01-12
US6596852B2 (en) 2003-07-22
FI965297A0 (fi) 1996-12-31
DK0770088T3 (da) 2005-05-30

Similar Documents

Publication Publication Date Title
DE69533923D1 (de) Cytokinin-designiertes lerk-5
ATE353906T1 (de) Cd27 ligand
ATE259377T1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
ATE296348T1 (de) Cytokin lerk-7
DE69737978D1 (de) Als 2f1 bezeichnetes rezeptorprotein
DE69334100D1 (de) Elk ligand, ein cytokin
DE69535719D1 (de) Fas-antigenbindender ligand
DE69232537D1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
ATE323770T1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
MX9700213A (es) Citocina novedosa designada como lerk-5.
DK0946591T3 (da) Klonede glucagon-lignende peptid-2 receptorer
ATE555126T1 (de) Relaxin-chimere polypeptide und deren herstellung und anwendung
IL138585A0 (en) Vertebrate batched -2 protein
EA199900253A1 (ru) Ptx-чувствительные g-протеины, их получение и применение
NO984233L (no) Cytokin kalt lerk-8
EA199900663A1 (ru) Новые белки, связывающиеся с рецептором 1 интерферона, кодирующая их днк и способы модуляции клеточного ответа на интерфероны
IT1208759B (it) Complesso di mobile composito tavolo-sedie,riducibile in condizionidi minimo ingombro

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0770088

Country of ref document: EP

REN Ceased due to non-payment of the annual fee